The myocyte enhancer factor 2A (MEF2A) promoted neuronal cell apoptosis in vitro and in vivo experimental models of Parkinson’s disease and some of its genetic variants associated with an increased risk of late-onset AD (Gonzalez et al., 2007; Wu et al., 2017). Here, MEF2A is linked to Alzheimer disease.